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ABSTRACT 
 
 
Antimicrobial Efficacy of Liposome Encapsulated Nisin and Nisin’s Inhibition Against 
Listeria monocytogenes in Fluid Milk at Different Storage Temperatures. (August 2009) 
Shannon Elise Schmidt, B.S., Texas A&M University 
Chair of Committee: Dr. Matthew Taylor 
 
Nisin is a naturally occurring food antimicrobial that inhibits many Gram-
positive pathogens, including Listeria monocytogenes, a bacterial pathogen responsible 
for ~500 deaths in the U.S. annually. Factors known to counteract the nisin activity in a 
food matrix include: antimicrobial interaction with food components, insolubility, 
protease inactivation, and target cell-driven envelope modifications. Encapsulating nisin 
in liposomes can help protect nisin functionality by regulating its introduction to the 
external environment. The objectives of this study were to determine the encapsulation 
efficiency (%EE) of nisin within liposomes as a function of encapsulation method and 
the capacity of liposomal nisin to inhibit L. monocytogenes in fluid milk. 
 Phosphatidylcholine (PC) and phosphotidyl-DL-glycerol (PG) were used to 
prepare three lipid molar formulations: PC, PC/PG 7:3, and PC/PG 6:4 (mol.%). 
Liposomes were formulated to entrap the self-quenching fluorophore calcein and nisin. 
Unencapsulated analyte was removed via size-exclusion chromatography, and percent 
EE was determined. To determine antilisterial activity of liposomes, fluid milk samples 
containing L. monocytogenes (4 log10 CFU/mL) in combination with liposomal or 
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unencapsulated nisin at 50 IU/mL were mixed and aerobically stored at 5°C and 20°C. 
Surviving L. monocytogenes were enumerated via plating on a non-selective 
microbiological medium after 0, 1, 3, 6, 12, 24, 48, and 72 hours of incubation. 
 Encapsulation of nisin via extrusion resulted in a mean EE% of 84.20%, 77.33% 
and 80.78% for PC, PC/PG 7:3, and PC/PG 6:4 liposomes, respectively. Freeze-thaw 
cycling formed liposomes without detectable fluorophore entrapment. L. monocytogenes 
populations grew to 5 log10 CFU/mL after 72 hours at 5°C and 8 log10 CFU/mL at 20˚C 
after 48 hours. Unencapsulated nisin exerted statistically greater inhibition of Listeria in 
skim milk compared to liposomal nisin, regardless of incubation temperature. No 
statistically significant differences in Listeria populations exposed to free or 
encapsulated nisin in whole milk were observed at either incubation temperature. Results 
indicate storage temperature and presence of milk fat exert greater influence then nisin 
delivery (free vs. encapsulated) over Listeria inhibition. Further research is needed to 
confirm these findings and develop more effective means of liposome entrapment of 
nisin for the inhibition of foodborne bacterial pathogens. 
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CHAPTER I 
INTRODUCTION: LISTERIA MONOCYTOGENES 
 
 The first reported case of human listeriosis occurred when a soldier in World 
War II developed meningitis. Since then, it has emerged as a major foodborne disease. 
Its surfacing resulted from several factors including medical progress, more 
immunocompromised individuals, changes in food processing methods, food preparation 
and handling, and food consumption habits (Rocourt and Cossart 1997). Listeria is 
considered a public health concern due to its severity, high case-fatality rate, and long 
incubation time that averages 31 days and ranges from 11-70 days (Rocourt and Cossart 
1997; Ryser and Marth 1999; Lorber 2007). There are several differences with Listeria 
compared to other foodborne pathogens such as a high mortality rate (20%-30%), its 
ability to cause spontaneous abortion, and its status as an intracellular pathogen (Bell 
and Kyriakides 2005; Jay and others 2005; FDA 2007; Painter and Slutsker 2007). 
Classification 
 This pathogen belongs to the genus Listeria within the Clostridium sub-branch. 
Listeria’s phylogenic position is partially dependent on its low G + C DNA content 
(36%-42%) (Rocourt and Cossart 1997; Ryser and Marth 1999; Jay and others 2005). 
Listeria has a low G + C DNA content because it contains fewer G and C DNA bases 
than A and T bases as compared to other bacteria. This is one of many features used to 
classify bacterial genomes, specifically Gram-positive bacteria. There are six species of 
Listeria, and only Listeria monocytogenes and Listeria ivanovii are pathogenic. However,   
____________ 
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L. monocytogenes is the only species considered a public health concern because L. 
ivanovii is primarily associated with animal disease. According to its numerical 
taxonomy, Listeria is closely related to lactic acid bacteria. Teichoic acids are found in 
the cell wall of Gram-positive bacteria and extend to the surface of the peptidoglycan 
layer. They are either covalently bonded to N-acetylmuramic acid of the peptidoglycan 
layer or linked to a D-alanine. Lipoteichoic acids are a combination of lipids and teichoic 
acids. The lipoteichoic acids present in most Gram-positive bacteria assist in Listeria’s 
virulence mechanisms (Ryser and Marth 1999). The lipoteichoic acids are 
polyphosphoglycerol substituted with a D-alanyl (D-Ala) ester or glycosyl residue 
(Abachin and others 2002). Studies have shown that mutants of Gram-positive bacteria 
deficient in D-Ala esters of lipoteichoic acids have an increased cell surface 
electronegativity (Abachin and others 2002). This allows for more efficient binding of 
cationic compounds and more susceptibility to cationic, pore-forming, antimicrobials. 
 The genus Listeria possesses several characteristics that distinguish it from other 
bacterial genera. This group contains regular, short rods that range from 1-2 µm in 
length (Holt and others 1994). The rods are found in single, short chains, and are 
arranged in V and Y forms, or in palisades (Holt and others 1994; Ryser 1999). Cells are 
Gram positive, do not produce spores, and are not encapsulated. When grown at 20-
25°C, Listeria can be motile by peritrichous flagella and are weakly mobile around 37°C 
(Holt and others 1994; Ryser and Marth 1999). They also move in a tumbling motion at 
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lower temperatures ~20°C by twisting and wriggling. Their speed will increase until they 
quickly move in different directions. 
Growth Requirements 
 Listeria is considered a psychrotroph by some and grows optimally from 30-
37°C, but it can also grow below 10°C (Holt and others 1994; Rocourt and Cossart 
1997). The microbe’s generation time slows to 30-40 hours at 4°C in fluid skim milk 
(Ryser and Marth 1999). Therefore, refrigeration is not sufficient to assure the safety of 
a food (Madigan and Martinko 2006). The bacterium’s virulence is increased at lower 
temperatures rather than higher, which can increase the bacterium’s ability to cause 
disease. Listeria requires at least four B vitamins (biotin, riboflavin, thiamine, and 
thioctic acid) and five amino acids (cysteine, glutamine, isoleucine, leucine, and valine) 
for sufficient growth (Jay and others 2005). Listeria spp. typically grow best around pH 
neutrality; however, they can grow at a pH range of 5.6-9.6 (Ryser and Marth 1999).  
Listeria can acquire enhanced resistance to acid stress due to growth phase-dependent 
acid resistance (AR) and adaptive acid tolerance response (ATR) (Gahan and others 
1996; Ferreira and others 2003). Adenosine triphosphate (ATP) presence enables 
enhanced resistance to lethal acid exposure and results from exposure of bacterial cells 
to mild acidic conditions over a period of time. Acid adaption may induce cross 
protection against heat, ethanol, oxidation, osmotic stress, and some antimicrobials 
(Ferreira and others 2003). ATR enhances Listeria’s ability to survive host challenges 
like exposure to gastric fluid, bile, competitive intestinal flora, and organic acids found 
in the small intestine (Ferreira and others 2003). After subjecting Listeria to non-lethal 
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acidic pH (4.8) for several hours its capacity to resist subsequent lethal acid stress 
increased (Phan-Thanh and others 2000). The amount of acidity Listeria can survive 
depends on the strain and kind of acid present. Its acid resistance is also growth-phase 
dependent. In the stationary phase Listeria has a natural acid tolerance to a certain 
extent. Listeria’s metabolism will decrease in an acidic medium, physiological processes 
will slow down, and fewer proteins will be synthesized (Phan-Thanh 2002). However, 
Listeria synthesizes a number of indispensible proteins that help it resist acidity (Phan-
Thanh 2002). In another study Listeria were subjected to acid and osmotic shock 
treatments after the beginning of growth and results showed shorter lag phases and 
longer generation times (Cheroutre-Vialette and others 1998).  As incubation 
temperature is raised above refrigeration, Listeria generation time will decrease (Bell 
and Kyriakides 2005). Listeria can grow in some low-pH foods, including fermented 
products depending on water activity (aw), food matrix, temperature, and other intrinsic 
factors (Lado and Yousef 2007). Experiments have shown the pathogen able to survive 
1-4 days in orange juice (pH 3.6) stored at 4°C and more than a year in cheddar cheese 
(pH 5.1) stored at 13°C and 6°C (Lado and Yousef 2007). The Pathogen Modeling 
Program (PMP) from the USDA showed D-values to decrease with pH in a log-linear 
fashion (USDA 2003; Lado and Yousef 2007). Listeria becomes more sensitive as 
acidity (pH <4.5) increases along with increase in temperature. Studies have shown that 
Listeria can alter its morphology during stressful environmental conditions. When the 
pH is greater than 9.0, Listeria will become filamentous or elongated chains will form 
that are 2X greater in length (Efstathios and others 2007). Once the stress is removed, 
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the cells will return to normal morphology and rapidly subdivide. They will grow 
optimally with an aw around 0.97 but have the ability to multiply at an aw as low as 0.90 
(Ryser and Marth 1999).  
Listeria are facultatively anaerobic or microaerophilic. Cells are catalase-positive 
and Cytochrome oxidase negative (Holt and others 1994; Delves-Broughton and others 
1996; Ryser and Marth 1999). The growth rate will increase in the presence of 
fermentable sugars, specifically glucose, due to the presence of glucose oxidase through 
the Embden-Meyerhof anaerobic glycolytic pathway, which yields pyruvate and lactate 
(Benedict 1990; Ryser and Marth 1999; Jay and others 2005). Listeria ferments lactic 
acid from glucose as the major metabolic end product. The pathogen is also capable of 
fermenting rhamnose but is unable to utilize xylose. Listeria completes the citric acid 
cycle and produces acetate and lactate with small amounts of isovaleric, isobutyric, and 
isohydroxy acids (Patchett and others 1991). Listeria is able to hydrolyze esculin into 
glucose and esculetin to form a black-colored complex with ferric iron (III) ions, a 
characteristic that has been exploited by microbiologists to identify the microbe in 
specific media like PALCAM, Fraser broth, and modified Oxford’s medium (MOX) 
(Van Netten and others 1989; Hammer and others 1990; Jay and others 2005; Gorski 
2008). 
Environment 
 L. monocytogenes is widely distributed throughout the environment. Its natural 
habitat consists of soil, water, and plant material (particularly those undergoing decay), 
animal feces, sewage, and silage (Ryser and Marth 1999; Jay and others 2005; Madigan 
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and Martinko 2006). Although widely distributed, the numbers of organisms in most 
environmental habitats are very low. The bacteria can survive longer under adverse 
environmental conditions than many other non-sporulating bacteria (Ryser and Marth 
1999). Listeria spp. have the ability to colonize, multiply, and persist on processing 
equipment making it a particular threat to the industry (Rocourt and Cossart 1997; Ryser 
and Marth 1999). Specifically, Listeria can attach to stainless steel, glass, wood, 
porcelain, iron, plastic, propylene, rubber, and paper eventually forming a biofilm (Lado 
and Yousef 2007). Attachment and biofilm formation occurs in the following sequence: 
cell deposition on the surface through hydrophilic interactions and presence of flagella, 
cell adhesion to the surface through hydrophilic interactions and presence of fibrils, 
surface colonization, biofilm formation, and biofilm development through growth and 
presence of capillary water channels (Lado and Yousef 2007). 
 Animals such as sheep, goat, and cattle are common reservoirs; therefore, foods of 
animal origin are usually associated with L. monocytogenes (Rocourt and Cossart 1997; 
Jay and others 2005; CIDRAP 2008). Commonly contaminated foods are uncooked 
meats and vegetables or unpasteurized milk. Some of the highest risk foods are ready-to-
eat (RTE), which are stored under refrigeration for long periods of time and not required 
to be fully reheated prior to consumption (Ryser and Marth 1999; Jay and others 2005; 
Madigan and Martinko 2006). Research has shown these foods to be cross-contaminated 
immediately post-processing with L. monocytogenes at greater than 100 CFU/g (Rocourt 
and Cossart 1997). In a survey of the prevalence of L. monocytogenes in RTE foods in 
the United States, smoked seafood, deli salads, and luncheon meats were found to harbor 
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the pathogen at rates of 4.31%, 2.36%, and 0.89%, respectively (Burnett and others 
2005). Previous experiments have shown that RTE turkey breast supported higher 
Listeria growth rates on growth curves than cured ham and cold-smoked salmon due to 
presence of salts of lactate or diacetate (Burnett and others 2005). The organism has also 
been found in raw milk, soft cheeses, fresh and frozen meat, poultry, seafood, and on 
fruits and vegetables (Jay and others 2005). Dairy, particularly milk, was the first and 
most often studied food product for L. monocytogenes (Rocourt and Cossart 1997; Jay 
and others 2005). Soft cheeses are of greatest concern because of the frequency of 
Listeria (2-10%) and the bacterial load (101-107 CFU/g) within the product due to their 
ability to grow in high salt, slightly acidic conditions, and in the presence of lactic acid 
bacteria (LAB) starter cultures (Rocourt and Cossart 1997; Cataldo and others 2007). 
The accidental use of raw milk in soft cheese due to inadequate pasteurization or 
improper use of raw milk for making cheese at home has created many problems with 
Listeria growth in soft cheeses. Listeria grows well in this matrix because soft cheeses 
are commonly treated with brine in the production process. This leads to increased salt 
concentrations that may inhibit competing organisms (Linnan and others 1988). The 
process temperature and short ripening times also drive Listeria transmission. Soft 
cheeses do not undergo a heat treatment (40˚C-50˚C) like hard cheeses, and soft cheeses 
usually do not go through a ripening process so they never develop a strongly acidic pH 
to reduce bacterial growth. However, the United States requires non-ripened cheeses 
(aged less than 60 days) to use pasteurized milk for their production (FDA 1998). 
Ripened cheeses (aged more than 60 days) are not required to use pasteurized milk for 
    8 
   
their production due to low water activity and pH content (FDA 1998). Many Listeria 
outbreaks have been documented with the primary vehicles being foods listed above. 
Incidence 
 In the United States, approximately 2,500 people develop listeriosis each year; of 
these, ~500 people die (CDC 2008). The incidence of listeriosis has continued to decline 
in recent years; from 1989-1993 the incidence declined from 7.4 to 4.4 million cases 
partially due to regulatory agencies enacting the zero-tolerance policy for processed 
meats (USDA 1993; Ryser and Marth 1999). In 1996 the incidence per 100,000 persons 
was 0.46 compared to an incidence rate of 0.27 in 2007 (CIDRAP 2008). However, as of 
2007, the national health objective of 0.24 incidence set for 2010 had not been met 
(CIDRAP 2008). The overall case-fatality rate of systemic or invasive listeriosis is 20%-
30% for epidemic and sporadic cases, and the mortality rate is higher (38%-40%) for the 
immunocompromised, elderly, pregnant women, and people with central nervous system 
(CNS) problems (Rocourt and Cossart 1997; CDC 2008). People with weakened CNS, 
cancer, or those using immunosuppressive medication following organ transplantation 
are at an increased risk of developing bacterial meningitis known as inflammation of the 
membranes and cerebrospinal fluid surrounding the brain and spinal cord. 
Cost of Illness 
 Listeriosis is a costly disease due to its severity, incidence of residual symptoms, 
and high case-fatality rate (Rocourt and Cossart 1997). Estimates for total costs of 
listeriosis cases in 2000 approximated $2.3 billion (Crutchfield and Roberts 2000). This 
amount was due to 2,493 cases, 2,298 hospitalizations, and 499 deaths (CDC 1999; 
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Crutchfield and Roberts 2000). In 1993, the estimated total costs of listeriosis were 
~$264 million. This total cost was determined from several subcategories. This includes 
acute illness medical costs of $61.7-$64.8 million. There were three case categories 
present for acute illness medical costs. Maternal hospitalized cases cost $3.1 million, 
newborn/fetus hospitalized cases cost $14.3-$17.4 million, and other adult hospitalized 
cases cost $44.3 million (USDA 1993). Medical and special education costs from 
chronic listeriosis, which was only present in newborn/fetal cases, cost $7.2 million 
(USDA 1993). Productivity losses from acute listeriosis cost $125.8-$154.4 million, 
while productivity losses due to chronic listeriosis cost $38.0 million per year (USDA 
1993). The estimated total cost for listeriosis has lowered some from 1993-2000, but it is 
still considered a costly disease.  
Foodborne Outbreaks 
 The first Listeria confirmed foodborne outbreak occurred during 1981 in Nova 
Scotia, Canada, over a six-month period (Rocourt and Cossart 1997; Ryser and Marth 
1999). There were 41 patients affected, and 37 were pregnancy-associated cases. The 
vehicle for Listeria transmission was found to be coleslaw. It is believed the cabbage 
used to make coleslaw was fertilized with sheep’s manure, which caused the cross-
contamination. During 1983 in Boston, Massachusetts 49 cases were confirmed over a 
two-month period with a case fatality rate of 29% (Rocourt and Cossart 1997; Ryser and 
Marth 1999). The illness was strongly associated with drinking a specific brand of 
pasteurized whole or 2 percent milk (Fleming and others 1985). The milk associated 
with disease came from a group of farms on which listeriosis in dairy cows was known 
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to have occurred at the time of the outbreak. Multiple serotypes of L. monocytogenes 
were isolated from raw milk obtained from these farms after the outbreak (Fleming and 
others 1985). At the plant where the milk was processed, inspections revealed no 
evidence of improper pasteurization. However, it is possible some of the Listeria cells 
survived the pasteurization process. The largest North American outbreak occurred 
during 1985 in California. There were 142 cases over an eight-month period with 93 
pregnant cases and 49 non-pregnant cases (Linnan and others 1988; Rocourt and Cossart 
1997; Ryser and Marth 1999). The case fatality rates were 32% and 37%. The source of 
contamination was determined to be Mexican Queso Fresco soft cheese due to 
inadequate pasteurization of the raw milk used to produce this cheese (Linnan and others 
1988). This outbreak helped determine Listeria has longer incubation periods (11-30 
days) than most foodborne pathogens (Ryser and Marth 1999). A four-year outbreak 
occurred during 1983-1987 in Switzerland affecting 122 cases due to soft cheese 
contamination. In 1989-1990 the United Kingdom suffered 300 cases from 
pate´(Rocourt and Cossart 1997). France had an outbreak in 1992 with 278 confirmed 
cases due to pork tongue cross-contamination. The contamination probably occurred 
during distribution (Rocourt and Cossart 1997). During 1997 in Italy, 1,566 children 
contracted febrile gastroenteritis from tuna and corn salad; 292 were hospitalized and 
87% of stool cultures were positive for L. monocytogenes (CIDRAP 2008). “Cleugh's 
Frozen Foods' [recalled] frozen strawberries sold to Jamba Juice locations in Arizona, 
Nevada, and Southern California during 2006 that was due to Listeria contamination”. It 
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created a scare to consumers that reduced confidence in the safety of the product (FDA 
2006). 
Listeriosis 
Listeriosis is an illness caused by the infectious bacterium Listeria 
monocytogenes. It is characterized by a sudden onset of fever, sever headache, vomiting, 
and other influenza-type symptoms (USDA 1993). Roughly 85%-95% of all listeriosis 
cases are attributed to food (USDA 1993). Listeriosis has caused premature death in 
fetuses, newborns, and some adults. Susceptible populations include neonates, the 
elderly, pregnant women, immunocompromised (people with predisposed disease 
leading to T-cell mediated immunity), and AIDS victims (Rocourt and Cossart 1997; Jay 
and others 2005; Madigan and Martinko 2006). Adults with listeriosis most frequently 
contract sepsis, meningitis, or meningo-encephalitis. Central nervous system symptoms 
may include fever, malaise, ataxia, seizures, and altered mental status (Painter and 
Slutsker 2007). Spontaneous abortion of a pregnancy is strongly associated with a 
decease in T-cell mediated immunity which is responsible for resistance to Listeria 
(Lorber 1990). Most cases of listeriosis during pregnancy occur in otherwise healthy 
women who show nonspecific symptoms that appear as a mild illness. During 
pregnancy, the form of listeriosis is bacteremia and virtually never meningitis even 
though meningitis is the most common form of listeriosis in other at risk groups. A 
quarter of patients have a bacteremic form of listeriosis showing fever, fatigue, myalgia, 
malaise and isolation of L. monocytogenes from blood cultures without evident foci of 
origin or metastatic infection (Lorber 1990; Ryser and Marth 1999). Most patients with 
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bacteremia have underlying conditions like hematologic malignancy or 
immunosuppression. In clinical cases of listeriosis, 30% occur in people younger than 3 
weeks old and people older than 40 years of age (USDA 1993). 
Infected pregnant women can transmit the illness to their newborns/fetuses 
before or during delivery by transplacental transmission (Painter and Slutsker 2007). 
Infants infected in utero may be aborted early on, stillborn, or are born with early onset 
neonatal septicemia (Lorber 1990; USDA 1993; Jay and others 2005). Infants infected at 
or shortly after birth can develop late onset neonatal meningitis and will age and develop 
chronic neurological complications. Babies infected shortly after birth will typically be 
premature with a low birth weight. They can develop respiratory issue including 
pneumonia and granulomatosis infantiseptica (Lorber 1990). Late onset neonatal 
infection is manifested as meningitis in the second to fourth week after birth.  
The infective dose of L. monocytogenes depends on many factors. These include 
the immunological status of the host, exposure to particular foods, and the virulence 
factors of the organism. Data indicates the amount of L. monocytogenes in contaminated 
food responsible for epidemic and sporadic foodborne cases is more than 100 CFU/g 
(Rocourt and Cossart 1997). However, the infective dose of L. monocytogenes is 
unknown but is believed to vary with the strain and susceptibility of the victim as stated 
earlier. Fewer than 1,000 total organisms may cause disease in cases associated with the 
consumption of raw and pasteurized milk (FDA 2007). 
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Pathogenicity 
 L. monocytogenes is one of the most invasive bacteria known because it can 
infect many different cells (macrophages, fibroblasts, hepatocytes, and epithelial cells). 
If L. monocytogenes is contracted orally, it will cross the intestinal barrier at the site of 
entry at epithelial cells or M cells in Peyer’s Patches (Rocourt and Cossart 1997; 
Madigan and Martinko 2006). Bacteria are then internalized by surrounding 
gastrointestinal (GI) cells to escape macrophage attack where they will survive and 
replicate. They are then transported by blood to regional lymph nodes. Upon reaching 
the liver and spleen, most Listeria are killed quickly (Rocourt and Cossart 1997). During 
the early phases of the illness, hepatocytes are the target for neutrophils and eventually 
for mononuclear phagocytes (Rocourt and Cossart 1997; Jay and others 2005; Madigan 
and Martinko 2006). Further spreading and infection may occur depending on the level 
of T-cell response. Therefore, infection is not localized at the site of entry and can 
involve many cell types and tissues (Rocourt and Cossart 1997). 
Intracellular Invasion 
 Listeria spread directly from cell-to-cell to shelter themselves from host 
defenses. Soon after entry into the target cell, the bacteria are internalized in membrane-
bound vacuoles. These vacuoles are lysed in less than thirty minutes, and the bacteria are 
released into the cytoplasm where they will begin to replicate (Rocourt and Cossart 
1997; Ryser and Marth 1999; Jay and others 2005). The protein toxin Listeriolysin O 
(LLO) belongs to a family of thio-activated, cholesterol-dependent, pore-forming toxins 
(CDTX) responsible for this mechanism (Kuhn and Goebel 2007). LLO will oligomerize 
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in the target cell membrane to form stable pores due to its affinity for cholesterol within 
the cell’s membrane. Once inside the cytosol, a surface protein ActA helps form actin 
tails that will cover the bacteria and rearrange into a polar tail (Rocourt and Cossart 
1997; Ryser and Marth 1999; Jay and others 2005). This tail will propel the organism 
toward the cytoplasmic membrane. Upon reaching the membrane, the bacteria push out 
to form a protrusion called a filopodium that has a bacterium at its tip (Jay and others 
2005). A neighboring cell then internalizes the protrusion through phagocytosis making 
a two-membrane-bound vacuole. The new vacuole is lysed and the invasion process is 
repeated. Specific virulence genes that include LLO and the two bacterial 
phospholipases, phosphatidylinositol-specific phospholipase C (PIPLC) and the broad-
range phospholipase C (PCPLC), aid this mechanism (Rocourt and Cossart 1997; Jay 
and others 2005). This is a very effective invasion method that allows Listeria to occupy 
many cells and organelles within the host. 
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CHAPTER II 
LIPOSOMES 
 
 Since the first observation of phospholipid vesicles (liposomes), liposome-
derived technologies have become one of the cornerstones of bio-nanotechnology 
(Bangham 1972; Jesorka and Ormar 2008). Liposomes are small vesicles formed from 
amphiphilic lipids suspended in an aqueous environment that enclose an aqueous core. 
Theses vesicles can incorporate many functional components within their interior 
making them very versatile. Material may be entrapped in the lipid bilayer or in the 
aqueous phase, depending on its inherent lipophilicity/hydrophilicity (Skeie 1994). 
Liposomes can be made entirely from naturally occurring substances and can be 
therefore nontoxic, biodegradable and non immunogenic (Lasic 1995). Due to liposome 
versatility and ability to act as targeted release-on-demand carrier systems for water and 
oil-soluble compounds, they have been used in a number of industrial applications 
including drug delivery, gene therapy, cosmetics, ecological preservation, and food 
processing (Lasic 1995; Laye and others 2008). Liposomes are predominantly composed 
of phospholipids that spontaneously form bilayers when polar solvents, such as water, 
are mixed with dried lipid. Polar head groups from phospholipids will orientate towards 
the polar, aqueous environment, while hydrophobic tails tend to cluster together to 
minimize their contact with water, forming a lipid bilayer as seen in figure 1 (Wiggins 
1990; Kim and Baianu 1991).  
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Figure 1-Liposome with Bilayer in Aqueous Solution. 
Phospholipid head groups represented by green spheres and hydrophobic tails represented by yellow lines 
(Wikimedia 2009). 
 
 
 
However, these vesicles can be formed from many lipid species and classes creating 
different polymorphic phases such as the bilayer or hexagonal (HII) organization (Hope 
and others 1985). Different methods of preparation will assist in determining the size of 
the vesicle making large or small unilamellar or multilamellar vesicles among other 
possibilities.  
Liposome Properties 
 The primary phospholipids used for the production of liposomes include the 
zwitterion phosphatidylcholine (PC) and the anionic phosphatidic acid (PA), 
phosphatidylglycerol (PG), phosphatidylserine (PS), and phosphatidylethanolamine (PE) 
(Jesorka and Ormar 2008). Each of these lipids may possess a different combination of 
fatty acid chains in the hydrophobic region of the molecule giving different degrees of 
saturation. Each phospholipid is unique and has complex phase transition profile. The 
gel to liquid crystalline phase transition temperature (TM) is defined as the temperature 
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required to induce a change in the lipid physical state from the ordered gel phase in 
which hydrocarbon chains are fully extended and closely packed to the disordered liquid 
crystalline phase where the hydrocarbon chains are randomly oriented and fluid (Taylor 
and others 2005; Voet and others 2006; Avanti 2009). There are several factors that 
influence the phase transition temperature such as acyl chain length, headgroup charge, 
headgroup species, and degree of unsaturation. Usually, the longer hydrocarbon chain 
lengths mean there will be higher phase transition temperatures (Voet and others 2006). 
Introducing a double bond puts a kink in the chain requiring lower temperatures to 
induce an ordered packing arrangement (Avanti 2009). Sometimes cholesterol is added 
to a system to improve stability. Cholesterol is the major sterol component in most 
mammalian membranes, and is not homogeneously distributed among different 
organelles. One of the specific physical features of cholesterol is the planar steroid ring, 
a conformationally rigid structure, which governs much of the interactions of cholesterol 
in a lipid bilayer (Raffy and Teissie 1999). Cholesterol lowers membrane permeability at 
elevated temperatures and modulates membrane-protein interactions thus imparting 
better stability (Samad and others 2007). Cholesterol decreases membrane fluidity thus 
creating rigidity because its steroid ring system interferes with the motions of fatty acid 
side chains (Voet and others 2006). When cholesterol is present in large amounts, it acts 
as a permeability barrier for the membrane by introducing conformational ordering of 
the lipid chain (Raffy and Teissie 1999). Specifically, it alters the freedom of formation 
of carbon molecules in the acyl chain. It increases its mechanical stiffness while keeping 
the membrane fluid.  
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Liposomes are most frequently classified by their size, and number of bilayers 
(lamellae). Liposomes can vary widely in size from <30nm referred to as small 
unilamellar vesicles (SUVs) to 20-100nm referred to as large unilamellar vesicles 
(LUVs) to >100nm called giant unilamellar vesicles (GUVs) (Kim and Baianu 1991; 
Taylor and others 2005; Samad and others 2007; Taylor and others 2007). These are 
vesicles with only a single bilayer membrane; however, liposomes with more than a 
single bilayer membrane are called multilamellar vesicles (MLVs) (Lasic 1995). Larger 
vesicles will have a better chance at trapping a higher volume, however sizes >300 nm 
will scatter light making them visible to the naked eye showing a cloudy appearance 
(Taylor and others 2005). Table 1 shows a summary of the different liposome 
classifications. These various sizes are a result of the many different preparations and 
methodologies used today.  
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Table 1- Size and Lamellae-Dependent Classification of Liposomesa  
 
Vesicle Type Abbreviation Diameter Size Number of 
Lipid Bilayer 
Small 
Unilamellar 
vesicle 
SUV 20-100 nm One 
Large 
Unilamellar 
vesicle 
LUV >100 nm One 
Giant 
Unilamellar 
vesicle 
GUV >1 micro meter One 
Oligolamellar 
vesicle 
OLV 0.1-1 micro 
meter 
~ 5 
Multilamellar 
vesicle 
MLV >0.5 nm 5-25 
aVesicle types with their abbreviation, size, and number of lipid layers (Kim and Baianu 1991; Lasic 1995; 
Taylor and others 2005; Samad and others 2007). 
 
 
 
Vesicle Preparation 
 Multilamellar vesicles were first prepared using a simple film-hydration 
technique (Bangham and others 1965). The lipid solution is initially dried either via 
evaporation, spray drying, or lyophilization to produce a thin film. The sample is then 
hydrated with an aqueous solution and mechanically agitated. Vesicles spontaneously 
form when the film is exposed to an excess volume of aqueous buffer and agitated 
(Lasch and others 2003). This produces vesicles that are heterogeneous in size, a major 
disadvantage, as well as, possible sample degradation occurring (Kim and Baianu 1991; 
Jesorka and Ormar 2008). They have large diameters, multiple internal compartments, a 
low entrapment volume, and are inconsistent from batch to batch (Mui and Hope 2007). 
The main advantage of MLVs is that their lipids are not subjected to harsh treatments 
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like exposure to organic solvents or high-intensity ultrasound.  MLVs can be 
transformed into unilamellar vesicles through various mechanical processing methods.  
LUVs are thought as the most useful liposome because they are more 
homogeneous than MLVs and have higher encapsulation efficiency than SUVs (Kim and 
Baianu 1991; Mui and Hope 2007; Samad and others 2007; Jesorka and Ormar 2008). 
This is due, in part, to their sufficiently large radius and single bilayer. Several common 
methods of preparation that are considered non-mechanical methods are reverse phase 
evaporation, detergent dialysis, and freeze-thaw.  
 SUVs consist of a single lipid bilayer and have a relatively homogeneous size 
distribution. Encapsulation efficiency for SUVs is around 1-2% of the original enzyme 
preparation (Skeie 1994). SUVs will spontaneously fuse when they drop below the phase 
transition temperature of the lipid forming the vesicle (Avanti 2009). There are several 
methods that produce SUVs including sonication, high-pressure homogenization, and 
extrusion all of which are considered mechanical methods.  
Reverse Phase Evaporation 
 In reverse-phase evaporation (REV) the lipid mixture and aqueous solution to be 
encapsulated are dispersed in an organic solvent. The system is subjected to 
homogenization forming an emulsion. The emulsion structure is similar to inverted 
micelles (hydrophilic headgroups interacting with aqueous phase while hydrophobic 
fatty acid tails interact with organic solvent) (Lasch and others 2003; Taylor and others 
2005; Samad and others 2007). The solvent is removed by evaporation creating a gel-
like state. The gel-like state collapses and some inverted micelles disintegrate resulting 
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in excess phospholipid that helps to form a complete bilayer around the remaining 
micelles (Winterhalter and Lasic 1993). This produces heterogeneous vesicles (100-1000 
nm) with high entrapment efficiencies (up to 65% of aqueous phase can be trapped 
within vesicles) (Lasch and others 2003). However, the material to be encapsulated is 
exposed to organic solvent that may lead to protein denaturation and complete removal 
of the solvent is almost impossible (Skeie 1994; Lasch and others 2003; Taylor and 
others 2005; Mui and Hope 2007).  
Detergent Depletion 
 This method is used for the removal of small molecular weight material from 
liposome dispersions that escaped entrapment and for the complete removal of 
detergents from mixed detergent lipid micelles to produce homogenous liposomes 
(Lasch and others 2003; Taylor and others 2005). Detergents are a class of molecules 
that disrupt or form hydrophobic and hydrophilic interactions among molecules in 
biological samples. Common detergents used include sodium cholate, 
alkyl(thio)glucosides, and alkyloxypolyethylenes (Lasch and others 2003). Sodium 
cholate is a water-soluble ionic detergent and is one of the least denaturing of ionic 
detergents. At concentrations > 9.5 mM, sodium cholate forms small micelles around 
(900-1,200 Da) that allows easy removal by dialysis or gel filtration, if needed (Pierce 
2006). Cholate and deoxycholate produce the most homogenous liposome populations 
(Lasch and others 2003). Alkyl(thio)glucosides and alkyloxypoly-ethylenes are nonionic 
detergents meaning they lack a charged group. At high concentrations nonionic 
detergents solubilize biological membranes by forming mixed micelles of detergent, 
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phospholipid, and integral membrane proteins. At low concentrations they may bind to 
the hydrophobic regions of most membrane proteins, making them soluble in aqueous 
solution; however, they do not form mixed micelles (Lodish and others 2000). Micelles 
are formed when more surfactant than lipid is present. As surfactant molecules are 
removed from the aqueous phase using dialysis, surfactant molecules present in micelles 
will be removed (Taylor and others 2005). This creates mixed surfactant-containing 
liposomes and further dialysis is required to completely remove the surfactant to produce 
surfactant-free liposomes. Other methods used to deplete the detergent include dilution, 
gel-filtration, and adsorption (Lasch and others 2003). The detergent used determines the 
size distribution of vesicles formed. Detergent depletion is a very flexible method 
because it allows the preparation of a large variety of liposomes and proteoliposomes. It 
is a mild treatment so even sensitive proteins and encapsulated materials can survive 
while physical (sonication, extrusion) and chemical treatments (organic solvents) can 
induce loss of functionality. However, this method is time consuming and small amounts 
of surfactant can stay in the system.  
Freeze-Drying Rehydration 
 Freeze-dried rehydration vesicles (FRVs) are formed from preformed vesicles to 
refine and improve their properties instead of simply producing them (Lasch and others 
2003). These vesicles are formed from preexisting liposomes that have been subjected to 
dehydration-rehydration cycles. In this method, lipids are hydrated with the aqueous 
mixture containing the material to be entrapped after which they are freeze-dried, 
leading to a dispersion of solid lipids in a finely subdivided form (Samad and others 
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2007). Rehydration above the gel-liquid crystalline phase transition temperature will 
cause the membranes to fuse and reseal to produce MLVs (Skeie 1994; Taylor and 
others 2005). These vesicles are much larger than the initial liposomes and high 
encapsulation efficiencies can be achieved (up to 45%) (Lasch and others 2003; Taylor 
and others 2005). To further improve encapsulation efficiencies, liposome may be 
subjected to multiple freeze-thaw cycles above their phase transition.  
Freeze-Thaw Cycling 
Freeze-thawing involves submerging a sample under water and in several 
different temperatures with large gradients. During freezing, solutes are expelled from 
the ice phase and the material to be encapsulated is concentrated in the residual fluid 
(Burger and others 2002; de Kroon and others 2005; Laye and others 2008). Small 
aggregates of neutral species begin to form followed by co-aggregation of the positively 
charged encapsulate species (Burger and others 2002). Electrostatic interaction of the 
positively charged solution and negatively charged lipids results in vesicle formation 
(Laye and others 2008). 
Sonication 
 Sonication applies sound (ultrasound) to agitate particulates. This method is 
among the first mechanical treatments of amphiphilic lipids (Mui and Hope 2007). 
Ultrasonication generates alternating low-pressure and high-pressure waves in liquids, 
leading to the formation and violent collapse of small vacuum vesicles. This event is 
called cavitation and it creates extreme pressure and temperature gradients in these 
vesicles along with powerful shear-forces. In these conditions, large liposomes 
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spontaneously form when mixed with aqueous solutions. High-shear forces will 
eventually lyse large liposomes to form smaller vesicles (Taylor and others 2005). There 
are two approaches to sonication. One is immersing a metal probe directly into a mixture 
of liposomes (Kim and Baianu 1991; Mui and Hope 2007; Samad and others 2007; 
Jesorka and Ormar 2008). This method is usually used for small volumes and requires 
high energy (Samad and others 2007). The second approach involves the mixture held in 
a glass vial and placed in a bath sonicator and is useful for large volumes. Unlike the 
probe, this method can be carried out in a closed container under nitrogen and cannot be 
contaminated with the metal from the probe tip (Kim and Baianu 1991). However, bath 
sonicators are preferred because they maintain a uniform energy distribution resulting in 
homogeneous liposomes. The mechanical agitation of sonication may create problems 
like enzyme activity reduction and foaming, which loses lipids.   
High-Pressure Homogenization and Microfluidizers 
 The main advantages of homogenized liposomes are their single bilayer membrane 
and small and homogeneous vesicle size (Lasch and others 2003). The processes work 
mostly under mild conditions, are cost-effective and may be scaled up easily (Bachmann 
and others 1993). Several types of homogenizers are available including the French 
pressure cell, Ultra-Turrax® high-shear mixers, and microfluidizers. Gap and 
interaction-chamber machines give high levels of energy dissipation and small particles 
where high-shear mixers give lower energy use and larger particle sizes (Lasch and 
others 2003).  
 The Microfluidizer is a high-pressure homogenizer that can quickly produce a 
    25 
   
large volume of liposomes in a continuous and reproducible manner without using 
sonication, detergents, solvents, or alcohols (Thompson and Singh 2006). 
Microfluidization is based upon the interaction between two fluid streams at high 
velocities. The aqueous buffer solution of pressurized in continuous flow, and split into 
two streams that are forced together at high velocities (>500 m/s) causing large 
phospholipid bilayer sheets to break into smaller pieces (Kim and Baianu 1991; 
Thompson and Singh 2006). Microfluidizers usually create smaller particle sizes than 
other homogenizes, which improves the macroscopic appearance and physical stability 
(Barnadas-Rodriguez and Sabes 2001).  
Extrusion 
Extrusion involves forcing a sample of large liposomes (LUVs) through 
cylindrical pores of filters uniform in size resulting in a homogenous population of 
smaller vesicles (SUVs) with vesicle sizes correlating to the size of filters used (Mayer 
and others 1986; Taylor and others 2005). By forcing large liposomes through smaller 
pores, they are sheared and resealed rapidly, consequently entrapping the targeted 
substance. The large vesicles are subjected to shear-induced tensions in the bilayer that 
makes the membrane unstable and smaller vesicles are produced as a result (Mui and 
Hope 2007).  Liposomes are usually subjected to multiple passes through membranes 
(MacDonald and others 1991). It is important for this method to be performed within 
solutions containing the material to be encapsulated because anything trapped before 
will leak out during extrusion and then be resealed within the new smaller liposomes 
(Taylor and others 2005; Jesorka and Ormar 2008).  Completion of extrusion at 
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temperatures above the main gel-liquid crystalline phase transition temperature is 
required because lipids in the gel-liquid state cannot be effectively extruded at low 
pressures (MacDonald and others 1991). This is most likely due to higher viscosities and 
decreased deformability. Hand held extruders have shown on average processing 
pressures ranging from 200-300 lb/inch2 proving significant pressure can be generated 
for benchtop procedures (MacDonald and others 1991). An example of a hand held 
extruder is the LiposoFast™ Mini-Extruder produced by Avestin Inc. (Ottawa, Ontario, 
Canada) shown in Figure 2.  
 
Figure 2­LiposoFast™ Mini­Extruder. 
Hand held benchtop extruder produced by Avestin Inc. The extruder uses two 1mL syringes that are luer 
lock at each end of the extruder. The sample is passed back and forth through membranes with specific 
pore sizes. The sample is sheared as it is passed through the pores, and the new vesicle size correlates to 
the size of filters used (Avestin 2009). 
 
 
 
Producing liposomes through extrusion offers several advantages such as the 
absence of residual organic solvent or detergents, the process works well with many 
types of lipids, and it produces liposomes homogeneous in size distribution and with 
high encapsulation efficiencies (Hope and others 1985; Mayer and others 1986). 
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Subjecting liposomes to several freeze-thaw cycles before extrusion may also allow for 
larger inter-lamellar spacing and much larger trapped volumes (Hope and others 1985; 
Mayer and others 1986; Mui and Hope 2007). Table 2 gives an overview of liposome 
preparation techniques and their resulting liposome classification. 
 
Table 2: Common Preparation Techniques for Different Types of Liposomesa 
 
Multilamellar 
preparation 
Unilamellar preparation 
MLV SUV LUV GUV 
Thin-film 
dehydration 
(evaporation-dried, 
spray-dried, or 
lyophilized lipid 
material) 
High-energy sonic 
fragmentation 
 
Extrusion 
 
High-pressure 
homogenization 
 
Solvent injection 
Freeze-thaw cycling 
 
Swelling in non-
electrolytes 
 
De-/rehydration 
 
Detergent dialysis 
 
Reverse evaporation 
De-/rehydration 
 
Electroformation 
 
Solid-film hydration 
 
Detergent dialysis 
aVarious liposome preparation techniques and liposome classification outcome (Bangham and others 
1965; Kim and Baianu 1991; Skeie 1994; Burger and others 2002; Lasch and others 2003; Taylor and 
others 2005; Mui and Hope 2007; Samad and others 2007; Jesorka and Ormar 2008; Laye and others 
2008). 
 
 
 
Liposomes in Drug Delivery  
 One of the first applications applied to liposomes was encapsulating drugs and 
therapeutics for localized delivery (Gregoriadis 1976b; Gregoriadis 1976a; 
Papahadjopoulos 1978). Liposomes are very effective in this area because they can 
enclose many different classes of substances such as antibacterial, antiviral, and 
anticancer drugs, as well as hormones, enzymes, nucleotides, steroids, and 
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bronchodilators. The aim of liposomal drug delivery is to achieve a high localization of 
active compounds at disease sites such as tumors, or inflammations (Ranade 1989; 
Jesorka and Ormar 2008).  Localization is the controlled release when a change in the 
liposome structure or in its reactivity promotes the release of encapsulated material. 
Controlled release helps to ensure release of the target-drug through a specific 
mechanism at the target site. There are two main controlled-release mechanisms. One is 
based on the development of an affinity reaction between the target and the liposome. 
The second is a triggered-release and involves incorporating an environmentally-
responsive (pH, temperature change, or light irradiation) molecule into the liposome that 
will cause structural changes in the bilayer membrane (Jesorka and Ormar 2008). 
Alteration of liposome surface charge has also been shown to enhance drug entrapment 
and release (Ranade 1989). Several liposomal drug delivery applications include: 
• Enhancing drug solubilization for Amphotericin-B, Minoxidil, Paclitaxels, and 
Cyclosporins  
• Protection of sensitive drug molecules like Cytosine arabinosa, DNA, RNA, Anti-
sense oligo-nucleotides, and Ribozymes 
• Enhancing intracellular uptake of anticancer, anti viral and antimicrobial drugs 
• Altering pharmacokinetic and bio-distribution for prolonged or sustained release of 
drugs with short circulatory half lives (Samad and others 2007) 
Liposomal aerosols have been used to treat respiratory disorders for sustained 
release, prevention of local irritation, reduced toxicity, and improved stability. These 
aerosols can treat diseases of the eye including dry eyes, keratitis, corneal transplant 
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rejection, uveitis, endopthelmitis, and proliferative vitro retinopathy by being used as a 
vector for genetic transfection and monoclonal antibody directed vehicles (Samad and 
others 2007). Liposomes can act as anti-infective agents by removing pathogens such as 
protozoa, bacteria, and fungus that reside in the liver and spleen. The polyene antibiotic, 
Amphotericin B, used to treat fungal infection because of renal toxicity has been 
encapsulated at normal doses for the treatment of these infections. Small and stable 
liposomes can target different tumors since they can circulate longer and pass through 
vessel walls into surrounding tissues through enhanced vascular permeability improving 
anticancer therapy (Gabizon 1992).  Several formulations of liposomal drug 
formulations are Doxil, EVACT™, DaunoXome, VincaXome, and Mikasom (NeXstar 
Pharmaceuticals, Inc., Boulder, CO).  
Liposomes in Gene Therapy 
 The aim of gene therapy is to deliver DNA, RNA, or antisense sequences to cells 
in order to alleviate symptoms or prevent diseases (Lasic and Templeton 1996; 
Templeton and Lasic 1999). Some major applications are gene replacement, addition of 
genes for production of natural toxins, sensitizing cells to other treatments, and over-
expression of highly immunogenic genes for immune self-attack. Diseases that could 
benefit from gene therapy by restoration of mutated genes and enhancement of the 
body’s response include cystic fibrosis, hemophilia, sickle cell anemia, immune system 
deficiencies, transmissible viral diseases (HIV, hepatitis), neurological diseases 
(Parkinson’s disease), and Alzheimer’s (Lasic and Templeton 1996). It was determined 
that cationic liposomes can electrostatically interact with anionic DNA, RNA, and 
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proteins, and complex into small stable particles that maintain increased transfection 
efficiencies (Templeton and Lasic 1999; Jesorka and Ormar 2008). Using liposomes for 
gene therapy has many advantages including: 
1. Unlimited size of nucleic acids that can be delivered 
2. Low cost and ease of producing liposome complexes that deliver therapeutics on 
a large scale 
3. Ability to target liposome complexes by colloidal or surface properties 
4. Lack of immunogenicity 
(Templeton and Lasic 1999) 
In order to target liposomes to a specific cite, ligands should be added by ionic 
interactions or by covalent attachments. Ligands are signal-triggering molecules that 
bind to a site on a target protein. Typically polyethylene glycol-conjugated (PEGylated) 
lipids are used to prepare noninteracting liposomes; however, normal liposomes can 
become sterically stable by incubation with PEG-lipid micelles making them interact 
with DNA.   
Liposomes in Cosmetics 
 In 1963, the use of lipid vesicles as systemic and topical drug delivery systems 
began attracting attention. The liposome bilayer structure contains phospholipids or 
sphingolipids which resembles natural membranes making this system applicable to the 
cosmetic industry (Arnaud 1995). Liposomes, depending on composition, can alter cell 
membrane fluidity and fuse with cells to deliver active drugs and ingredients to the 
target site (Betz and others 2005). Some experts believe liposomes do not penetrate as 
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intact vesicles or permeate the skim, but deform into fragments (Jesorka and Ormar 
2008). Liposomes offer advantages because the lipids used are well hydrated and can 
reduce the dryness of the skin, which is a primary cause for its ageing. The vesicles 
within creams, ointments, and other solutions will deliver drugs in a concentration 
dependent manner across the stratum corneum to the epidermis and dermis (Betz and 
others 2005). Liposome cosmetics range from pastes (creams, gels, and ointments) to 
formulations containing various extracts, moisturizers, antibiotics, and recombinant 
proteins for wound or sunburn healing (Lasic 1995). Due to their high and long lasting 
moisture content, most products are anti-ageing creams. Other products include 
sunscreens, perfumes, hair conditioners, and aftershaves. It should be noted that simple 
liposome formations do not allow penetration into the lower epidermal layers of the skin 
and therefore, are of minor value as transdermal drug delivery systems (Geho 1995; 
Jesorka and Ormar 2008). 
Liposomes in Food Industry 
 Food ingredients are encapsulated in liposomes for the same reason many other 
compounds are, and this is to improve stability of the ingredients by protecting them 
from metal ions, pH, free radicals, or enzymatic degradation (Reineccius 1995; Gibbs 
and others 1999). Liposomes work well for the food industry because they are natural, 
biodegradable, non-toxic, and versatile systems for both water and oil soluble 
components. Main applications within the field include altering the texture of food 
components, encapsulation of ingredients, additives, and antimicrobials, controlled 
release of flavors, and increasing the bioavailability of nutritional components like 
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vitamins and minerals (Reza Mozafari and others 2008). Table 3 shows various food 
ingredients that have been encapsulated over the years.  
 
Table 3-Various Encapsulated Food Ingredientsa 
 
Ingredients Specific Compounds Applications References 
Favoring agents (oils, 
spices, and seasonings 
Citrus oil, peppermint, 
tumeric, paprika 
Flavors are delicate and 
usually volatile, 
encapsulating them 
creates protection from 
evaporation, chemical 
reactions, oxidation, or 
migration within food. 
(Cheetham 1999; 
Barbosa-Canovas and 
others 2005) 
Sweeteners Aspartic acid Encapsulating 
sweeteners reduces their 
hygroscopicity, 
improves their 
flowability, and 
prolongs their sweetness 
perception  
(Schobel and Yang 
1989) 
Acids Ascorbic acid, fumaric 
acid, lactic acid, malic 
acid  
For flavor modifiers, 
preservatives, and 
processing aids for 
dough conditioners, and 
cured meat processing 
(Barbosa-Canovas and 
others 2005) 
Lipids Omega-3 fatty acids, 
carotenoids, polysterols 
Encapsulation helps 
stabilize fatty acids from 
rancidity, and 
autoxidation, which 
increases shelf-life. 
Used in infant formulas, 
bread mixes, fish oil 
capsules 
(Hoch 1997; Schrooyen 
and others 2001) 
Enzymes  Chymosin (milk 
coagulant enzyme) 
Enzyme encapsulation 
in liposomes provides  
good distribution in the 
curd and prevents 
interaction with milk 
proteins at the vat stage 
allowing shortened 
coagulation times. 
Enzymes can maintain 
viability by avoiding 
exposure to ions, 
protons, and free 
radicals. 
(Picon and others 1994; 
Barbosa-Canovas and 
others 2005) 
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Table 3 Continued    
Ingredients Specific Compounds Applications References 
Microorganisms Lactobacillus, 
Bifidobacterium,  
Encapsulation helps in 
segregating the bacterial 
cell from the adverse 
environment of  
the product thus 
potentially reducing cell 
loss. Encapsulation 
helps increase the 
survival and delivery of 
microorganisms. This is 
used within the dairy 
industry to protect 
probiotics within 
products.  
(Sultana and others 
2000; Annan and others 
2007) 
Antioxidants Flavonoids, 
Cyclodextrins,  
Encapsulation enhances 
solubility, dissolution 
rate, membrane 
permeability and 
bioavailability drugs.  
Improves stability to air 
and light. Flavonoids 
have been added to 
broccoli and other 
vegetables. 
(Calabro and others 
2004; Duncan 2006) 
Preservatives Salt Controls water 
absorption, rancidity, 
and yeast growth in 
meat products, pretzels, 
and yeast dough 
(Shahidi and Han 1993; 
Barbosa-Canovas and 
others 2005) 
Vitamins and Minerals Vitamins C, A, D, K, 
beta-carotene, B group 
 
Iron, Calcium,  
Encapsulation provides 
better stability, extends 
shelf-life, protects from 
oxidation. Used in dried 
milk, juices, orange oil, 
fluid milk. 
(Schrooyen and others 
2001; Duncan 2006) 
Fragrances  Encapsulation helps 
control fragrance 
evaporation, interactions 
with other components, 
oxidation and chemical 
degradation in air 
fresheners, perfumes, 
etc. 
(van Soest 2007) 
aIngredients that have been encapsulated for the food industry. 
  
One of the first studied liposome applications in food products was for reducing 
the ripening time and enhancing flavor development in cheese production (Law and 
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King 1985; Alkhalaf and others 1988; Kirby 1990; Law and King 1991; Lasic 1995). 
Due to the longevity of ripening, it is a substantial cost of producing cheeses. Therefore, 
reducing the time required is of great benefit to the industry. Incorporating enzymes into 
cheese has shown to reduce production times; however, addition of free enzymes in milk 
causes premature proteolysis. These enzymes are soluble in water and are inactivated 
during curd formation resulting in unfavorable curd consistency and low yields (Arnaud 
1995; Reineccius 1995; Gibbs and others 1999; Reza Mozafari and others 2008). 
Experiments in a Saint-Paulin cheese demonstrated up to 60% of liposomal-entrapped 
enzyme was retained whereas only 20% of free enzyme was retained. Within fifteen 
days of ripening, the liposome treated cheese had achieved an equivalent level of 
proteolysis as the non treated cheese at 45 days (Arnaud 1995).  
 Many vitamins are unstable to processing and react to many environmental 
stimuli. Encapsulation has shown to be beneficial by increasing their stability and 
protecting them from the environment. Ascorbic acid (Vitamin C) and α-tocopherol 
(Vitamin E) are susceptible to oxidation and both are stabilized after encapsulation. 
Ascorbic acid showed a 50% survival after refrigerated storage for 50 days compared to 
the free control, which was fully degraded after 20 days (Arnaud 1995; Reineccius 
1995). Vitamin E is more effective at preventing lipid oxidation when in liposomes 
versus in free form because it is kept from dissolving in the oil phase. 
 Other ingredients that have benefitted from encapsulation are acidulants because 
it increases the shelf life of their flavors and prevents loss of color due to controlled 
release. Lactic and citric acids enhance flavors and reduce production times in cured 
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meats like pepperoni, hard salami, and summer sausages (Gibbs and others 1999). 
Sodium bicarbonate can be encapsulated to prevent it from reacting with acid and water, 
providing uniformity. Sodium chloride is encapsulated to increase flow ability and 
reduce clumping and caking. Sweeteners can be degraded by temperature and moisture, 
therefore, encapsulating them allows for slow release during chewing and flavor 
retention (Gibbs and others 1999).  
 To prevent spoilage in various cheeses, Thapon and Brule (1986) encapsulated 
the antimicrobials lysozyme and nisin. One important reason for this is the addition of an 
antibiotic directly to the cheese curd would kill its starter culture (Reza Mozafari and 
others 2008). Antilisterial effects of pediocin AcH were seen upon encapsulation of 
bacteriocin in beef tallow and muscle slurries (Degnan and Luchansky 1992). 
Encapsulation of nisin has many advantages such as reducing or prohibiting nisin’s 
affinity to non-target components, lengthening the time of its preservative effects, 
decreasing the risk of resistant strains developing, and providing a means of targeting the 
bacteria (Reza Mozafari and others 2008). Benech and others (2002b) tested 
encapsulated nisin Z in liposomes composed of phosphatidylcholine (PC) and 
unencapsulated nisin in a cheese-milk solution at a final concentration of 300 IU/g 
cheese. They found that Listeria innocua counts were reduced by 1.5-3.0 logs within 6 
months (Benech and others 2002a). Laridi and others (2003) tested several commercially 
prepared proliposomes encapsulated with nisin against the effects of fatty-acid 
composition, pH, cholesterol, and nisin Z content on the encapsulation efficiency (EE) of 
the liposomes. Hydrogenated PC liposomes, lower cholesterol concentration, lower pH 
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(3.6) allowed for higher EE while higher percentages of unsaturated fatty acids did not 
influence the EE (Laridi and others 2003).  
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CHAPTER III 
NISIN 
 
 Nisin is an antimicrobial polypeptide or bacteriocin that was discovered in 1928 
by researchers during cheese production when a ‘lactic streptococci’ inhibited the 
growth of Lactobacillus cheese starter cultures (Rogers and Whittier 1928). Nisin was 
further characterized by the National Institute for Research in Dairying and given the 
name nisin (Whitehead 1933; Mattick and Hirsch 1947; Delves-Broughton and others 
1996). Its name is derived as ‘Group N Streptococcus Inhibitory Substance’ (Hurst 
1981). The suffix ‘-in’ was commonly used for antibiotics; however, nisin is considered 
a bacteriocin because it lacks the key attributes that make antibiotics unsuitable for food 
usage. Several attributes include: nisin not persisting in the body or environment, and it 
is not associated with development of bacterial resistance to nisin itself or to any 
medically important antibiotic (Thomas and others 2000).  
 The first commercial extract of nisin called Nisaplin® was produced in 1957 by 
Aplin & Barrett, Ltd. (Norman Hansen 1993; Delves-Broughton and others 1996; 
Thomas and Delves-Broughton 2005). Nisaplin® has a standard potency of 1 million 
International Units per gram and contains ~2.5% nisin A along with salts and milk solids 
from milk fermentation by Lactococcus lactis subspecies lactis (Thomas and Delves-
Broughton 2005). The Joint Food and Agriculture Organization/World Health 
Organization (FAO/WHO) Committee on Food Additives approved nisin for use in food 
in 1969. Nisin is currently approved as a food preservative in over 50 countries. It was 
given generally recognized as safe (GRAS) status in the United Stated in 1988 by the 
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Food and Drug Administration (FDA) (FDA/HHS 1988; CFSAN 2008). Nisin contains 
several characteristics that make is suitable for food preservation. It is non-toxic to 
humans, is produced by a bacterium not known to exert pathogenesis against humans, is 
not used for clinical therapies, and is digested quickly. 
Chemical and Physical Properties 
 Nisin is an antimicrobial polypeptide that is produced during milk fermentation 
by the organism Lactococcus lactic subspecies lactis. It is a bacteriocin meaning it has 
the ability to kill or inhibit other bacteria. It is classified as a Class Ia lantibiotic due to 
its structure. Lantibiotics are a family of membrane active peptides that contain unusual 
amino acids and lanthionine rings. These are specifically thioether amino acids 
lanthionine and B-methyl lanthionine and also modified amino acids like dehydrated 
serine and threonine (Klaenhammer 1993; Montville and Chen 1998; Thomas and others 
2000; Wiedemann and others 2001). It is considered a Group A lantibiotic because it has 
a linear structure rather than a circular structure like Group B lantibiotics. Nisin is 
comprised of 34 amino acid residues and has a molecular mass of 3510 Daltons. It has 5 
internal ring structures (Rings A-E) formed by disulfide bridges that are contributed by 
lanthionine and B-methyl lanthionine as seen in figure 3 (Gross and Morell 1971; 
Klaenhammer 1993). Ring A is formed by lanthionine and rings B-E by four B-methyl 
lanthionine residues (Thomas and others 2000; Cheigh and Pyun 2005; Thomas and 
Delves-Broughton 2005). The B-methyl lanthionine bridge is between residues 8 and 11 
while the lanthionine bridge is between residues 3 and 5 or 3 and 7 (Gross and Morell 
1971).  
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Figure 3-Structure of Nisin A. 
Nisin is comprised of 34 amino acid residues and contains 5 internal ring structures formed by disulfide 
bridges (Gross and Morell 1971). 
 
 
 
There are two forms of nisin, which are nisin A and nisin Z. They differ at position 27 
where nisin A has a histidine and nisin Z has an asparagine residue (Cheigh and Pyun 
2005). Nisin carries a poly-cationic charge due to three lysine residues and one histidine 
residue (nisin Z) or two histidine residues (nisin A). It is an amphiphilic molecule 
because it is hydrophobic at the N-terminus and hydrophilic at the C-terminus (Thomas 
and others 2000).   
Stability and Solubility 
 It is important to understand the stability and solubility of nisin when using it as a 
food preservative. Most notable is that its stability and solubility drastically increase as 
the pH is lowered and become less stable and soluble as pH is raised to neutral and 
alkaline levels (Hurst 1981; Delves-Broughton 1990; Liu and Hansen 1990; Rollema and 
others 1995). It is optimally stable around pH 3-3.5 (Thomas and Delves-Broughton 
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2005). It is so stable that at pH 2 it can withstand autoclaving temperatures (115°C to 
121°C) without inactivation, but 40% of its activity is lost at pH 5 and more than 90% is 
lost at pH 6.8 (Hurst 1981; Rollema and others 1995; Delves-Broughton and others 
1996). Pasteurization temperatures are less damaging to nisin. During standard 
processed cheese manufacturing, as least 80% activity will be retained (Delves-
Broughton and others 1996). It is not known whether nisin instability at high pH is a 
consequence of denaturation, chemical modification, or configuration changes. At 
alkaline pH the reactivity of unsaturated amino acids will undergo a variety of additional 
reactions that may contribute to this instability (Rollema and others 1995). The dehydro 
residues become susceptible to modification by nucleophiles that are present at high pH 
like hydroxide ions, deprotonated amines, and deprotonated hydroxyl groups (Liu and 
Hansen 1990; Thomas and others 2000; Thomas and Delves-Broughton 2005). 
Reactions with these nucleophiles can be intermolecular or intramolecular and possibly 
cause cross-linking that will form large aggregates. Buffer concentration can also affect 
nisin solubility because nisin is inversely and linearly proportional to phosphate buffer 
concentration. Certain food components have been shown to protect nisin during heat 
processing compared to buffer solutions (Liu and Hansen 1990; Delves-Broughton and 
others 1996)   
Antimicrobial Spectrum 
Nisin shows antimicrobial activity against many Gram-positive bacteria but little 
to no activity against Gram-negative bacteria. Nisin’s antimicrobial spectrum is in a 
concentration dependent; the cytoplasmic membrane is the primary site of porulation in 
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vegetative cells. Nisin will bind to the membrane, insert and orient itself, create a pore 
upon binding to peptidoglycan precursor molecule named Lipid II, and destroy the 
transmembrane potential causing rapid efflux of ions, amino acids, and ATP out of the 
cell resulting in death. Nisin is usually sporostatic rather then sporicidal. However, 
spores are sensitive to nisin and sensitivity increases with increasing heat damage and 
acidic conditions (Fowler and Gasson 1991). Nisin’s activity against spores does not 
affect the germination process. Instead, nisin prevents post-germination swelling and 
later spore outgrowth (Morris and others 1984; Thomas and others 2000). The mode of 
action will be covered in greater detail in the following paragraphs. 
The outer membrane of Gram-negative bacteria does not allow nisin to reach the 
cell membrane without altering the permeability of the outer membrane. It has been 
shown that chelators remove divalent cations like Ca2+ and Mg2+ ions from the outer 
membrane, destabilizing it and releasing phospholipid and lipoproteins (Delves-
Broughton 1993; Boziaris and Adams 1999). Chelators are compounds that can 
sequester metal ions and form stable metal complexes. Examples of chelators include 
ethylenediamine tetraacetic acid (EDTA), some acid salts (e.g. citrate), and 
pyrophosphate. Other agents can remove lipids and phospholipids from Gram-negative 
cell walls making them more sensitive to nisin like citric acid, lactates, and 
polyphosphates. Sub-lethal heating, freezing, hydrostatic pressure, or organic acids that 
can sensitize the cell wall and expose the membrane to nisin will increase its 
antimicrobial activity towards Gram-negative bacteria (Ganzle and others 1999; Thomas 
and Delves-Broughton 2005).  
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Mode of Action 
 Nisin acts upon vegetative cells at the outer membrane by binding and inserting 
itself into the membrane, forming pores, and destroying the proton motive force. Due to 
the cationic and amphiphilic nature of nisin, it has a strong affinity for anionic lipids in 
many membranes. Nisin attaches to the cytoplasmic membrane through electrostatic 
interaction of the negatively charged lipids present in the membrane to the positively 
charged C-terminus region of nisin (El-Jastimi and Lafleur 1997; Breukink and Kruijff 
1999; Bonev and others 2000). There is no significant binding of nisin to vesicles with 
zwitterionic lipids showing the affinity of this peptide is greatly dependent on the lipid 
charge (El-Jastimi and Lafleur 1997). It has been determined that nisin needs an 
energized membrane to dissipate the membrane potential in the process of causing cell 
leakage (Abee 1995; Breukink and Kruijff 1999). Binding of nisin induces a change in 
the secondary structure that involves conformational reorganization. It specifically 
promotes the formation of beta-turns (El-Jastimi and Lafleur 1997; Breukink and Kruijff 
1999). 
 Once nisin binds to the membrane, its amphiphilic properties allow it to insert 
into the membrane at the lipid phase. This is done with the help of lipid II, the 
bactoprenol-bound peptidoglycan precursor for cell wall synthesis (Wiedemann and 
others 2001). Lipid II is considered a key element during synthesis of bacteria cell walls. 
The undecaprenyl tail of lipid II is used as a carrier that transports the peptidoglycan 
subunit from the cytoplasm to the extracellular domain (Hsu and others 2002). The N-
terminal region of nisin first recognizes the lipid II headgroup, and a tight nisin/lipid II 
    43 
   
complex is formed. The amphiphilic nature of nisin along with lipid II allows it to insert 
into bilayers in a perpendicular orientation on the membrane interface (Hsu and others 
2002; Hasper and others 2004). This complex is also anchored onto the membrane by the 
undecaprenyl tail of lipid II. Subsequent conformational rearrangements take place due 
to aggregation of the nisin/lipid II complexes(Wiedemann and others 2001; Hasper and 
others 2004). Specifically, large chemical shift perturbations were found for the first two 
rings (A and B) (Lubelski and others 2008).  
 Multiple molecules of nisin and lipid II are assembled at the interface of the 
bilayer forming pores via an intermediate state called the prepore complex B (Hasper 
and others 2004). The pores produced are uniform in size and are very stable with 
increased lifetimes (6 seconds) compared to pores in the absence of lipid II 
(milliseconds). The final pore complex formed consists of 8 nisin and 4 lipid II 
molecules (Hasper and others 2004). Upon pore formation, the C-terminus translocates 
across the membrane (Breukink and Kruijff 1999). When the C-terminal of nisin is 
inserted into the membrane, the pore-forming process is complete. The presence of pores 
causes inhibition of amino acid uptake, and small metabolites, ions (K+), cellular ATP, 
or solutes begin to flow out of the bacterial cell resulting in cell death (Abee 1995; 
Thomas and Delves-Broughton 2005).  
Factors Affecting Nisin Action 
 Several factors in foods are known to counteract the action of nisin. Bacteriocin 
activity in food matrices may be affected by changes in the solubility and charge of 
bacteriocins, binding and interaction of bacteriocins to food components, inactivation by 
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proteases, and target cell envelope changes that occur in response to environment factors 
(Ganzle and others 1999). Heat treatments with higher temperatures and longer 
processes result in a greater nisin loss due to structural changes in the antimicrobial. In 
foods that are non-heat treated or are minimally processed, nisin can be degraded during 
storage by proteolytic enzymes developed from microbial, plant, or animal origins 
(Delves-Broughton and others 1996; Abee and Delves-Broughton 2003). Nisin is shown 
to work better in liquid and homogenous foods because it is more evenly distributed 
throughout the matrix. Phospholipids in meat are suggested to cause binding of nisin, 
making it unavailable (Delves-Broughton and others 1996). Some food additives such as 
sodium metabisulfite (antioxidant, bleaching, and antimicrobial agent) and titanium 
dioxide (whitener) have been shown to act as antagonists and degrade nisin (Abee and 
Delves-Broughton 2003; Thomas and Delves-Broughton 2005). Divalent and trivalent 
cations (Ca2+, Mg2+, or Gd3+) reduce efficiency of nisin Z against L. monocytogenes 
because they interact with certain negatively charged phospholipid headgroups (Gupta 
1968; Thomas and Delves-Broughton 2005). Divalent cations like Mg2+ bind to anionic 
phospholipids resulting in an enhanced rigidity of the cytoplasmic membrane and a 
reduced affinity of nisin to the cytoplasmic membrane (Ganzle and others 1999).  
Several factors in dairy products limit the activity of nisin, such as its adsorption 
to fat and the surface of protein globules, a heterogeneous distribution in dairy matrices, 
and the inhibition of non-resistant starter cultures (Sobrino-Lopez and Martin-Belloso 
2008). Due to its hydrophobic nature, nisin will bind to fat in foods which interferes with 
uniform distribution making nisin unavailable for bacterial inhibition (Delves-Broughton 
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and others 1996). Several studies have shown that activity of nisin decreases as the milk 
fat concentration increases (Jung and others 1992; Bhatti and others 2004; Sobrino-
Lopez and Martin-Belloso 2008). Bhatti and others (2004) determined phospholipids in 
2% or higher fat market milk bound a larger portion of nisin making it unavailable to 
react with the cell membrane of L. monocytogenes. Skim milk was not affected to the 
extent of the higher fat content milk so similar nisin concentrations were sufficient to 
disrupt the listerial cell membrane (Bhatti and others 2004). It is possible to use 
emulsifiers, which function to reduce surface tension effects that are elicited between 
polar and nonpolar molecules, to prevent binding of nisin to milk fat globules. The 
surfactant Tween 80® has the ability to displace proteins or peptides such as nisin from 
milk fat globules and restoring or retaining its activity in milk (Jung and others 1992; 
Bhatti and others 2004; Sobrino-Lopez and Martin-Belloso 2008). 
Nisin Resistance 
It is also possible for bacteria to develop resistance against nisin, because they 
respond to acid, osmotic, and thermal stresses in the environment (Bonnet and others 
2006). These responses increase their resistance and virulence. Many Gram-positive 
bacteria have been shown to be resistant to nisin because they have the ability to 
synthesize the enzyme nisinase that can inactivate nisin. Another resistance mechanism 
involves adaptation of cells by subjecting them to sub-lethal concentrations of nisin over 
a period of time. Several studies have shown L. monocytogenes mutants can easily be 
produced in the laboratory by exposure to high concentrations of nisin (Harris and others 
1989; Ming and Daeschel 1993; Mazzotta and Montville 1997). These adaptations were 
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shown to develop from changes in the cell envelope specifically in the cell membrane 
and peptidoglycan. Researchers have shown nisin resistant L. monocytogenes possessed 
lipids with higher phase transition temperatures, higher percentage of straight-chain fatty 
acids, and lower percentage of branched-chain fatty acids (Ming and Daeschel 1993; 
Crandall and Montville 1998; Li and others 2002; Abee and Delves-Broughton 2003) 
This resulted in decreased fluidity of the membrane, which decreased the efficiency of 
nisin pore formation in the resistant mutant. Listeriae are known to resist lethal acid after 
exposure to mild acidic conditions. This response is referred to as the acid tolerance 
response (ATR). Bonnet and Montville (2006) proved ATR-induced L. monocytogenes 
cells survived for 30 days at 4°C in the presence of nisin unlike the control. It is possible 
ATR protects L. monocytogenes because these resistant mutants have more rigid 
membranes due to changes in the proportion of fatty acids.  
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CHAPTER IV 
MATERIALS AND METHODS  
Culture Resuscitation and Maintenance  
 Listeria monocytogenes strain Scott A (LM SA) was obtained from Texas A&M 
University Department of Animal Science Food Microbiology Laboratory culture 
collection and kept on tryptic soy agar (TSA) slants (Becton Dickinson, Sparks, MD) at 
4°C. Revival was completed by transferring LM SA three times in tryptic soy broth plus 
0.6% yeast extract (TSB-YE) (Becton-Dickinson) at 35°C for 24 hr for full recovery of 
the cells. The first day LM SA was co-transferred from the slant into Fraser broth 
(Becton Dickinson) and on PALCAM medium (Becton Dickinson) to confirm correct 
phenotype (esculin hydrolysis). The second day LM SA was transferred from Fraser 
broth into TSB-YE and streaked onto TSA plus 0.6% yeast extract (TSA-YE). The third 
day LM SA was transferred a third time into TBS-YE and streaked onto TSA-YE. All 
broths and plates were incubated aerobically at 35°C for 24 hours per transfer.  
Antimicrobial Preparation 
 Nisin (CAS# 1414-45-5) (2.5% nisin; 1 million IU/g) from Sigma-Aldrich Co. 
(St. Louis, MO) was solubilized in 0.02M HCl (EM Science, Gibbstown, NJ) at a 
concentration of 0.1 g/10 mL (10,000 IU/mL). The stock was submerged in boiling 
water for four minutes, cooled, and stored at 4°C overnight. Each day a new working 
stock was prepared at a concentration of 50 IU/mL using 0.1X phosphate buffer saline 
PBS (0.017M KH2PO4, 0.05M Na2HPO4) (Mallinckrodt Chemicals, Phillipsburg, NJ), 
and (1.5M NaCl) (Sigma-Aldrich Co., St. Louis, MO) adjusted to pH 7.4.  
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Fluorescence Probe Preparation 
 Calcein (CAS# 1461-15-0) (Sigma-Aldrich Co.) was solubilized in 1.0 M NaOH 
(Fisher Scientific, Fair Lawn, NJ) to a concentration of 50 mM and adjusted to pH ~ 9.0. 
The calcein was stored at room temperature in an amber vial to keep from reacting with 
light.  
Liposome Preparation and Encapsulation via Extrusion  
 Egg-sourced L-α-phosphatidylcholine (PC) and L-α-phosphatidyl-DL-glycerol 
(PG), obtained solubilized in chloroform from Avanti Polar Lipids (Alabaster, AL), was 
used as major components of liposome formulations. Three different lipid molar 
combinations were prepared to a concentration of 60 mM: PC, PC/PG 70:30 (mol. 
fraction), and PC/PG 60:40 (mol. fraction). Each lipid formulation was prepared and 
solvent was evaporated under nitrogen gas. Any traces of chloroform were removed 
using a vacuum desiccator for 15 minutes and then refrigerated at 4°C inside the oxygen 
free environment overnight to prevent lipid oxidation. Each lipid combination was 
rehydrated using 0.5 mL of phosphate buffer saline (PBS) containing 50 mM of the 
fluorescent probe calcein (Sigma-Aldrich St. Louis, MO) with 50 IU/mL nisin (Sigma-
Aldrich, St. Louis, MO) the day after desiccation. Tubes were agitated to remove lipid 
from the test tube walls and allow vesicle formation. All tubes were then subjected for 
four cycles of freeze-thawing. Liposomes were immersed in 0°C water, tepid water, and 
60°C water for 11 seconds each in sequential order. Tubes were vortexed for 8-10 
seconds following each cycle. Each formulation was then passed 7 times each through 
sandwiches of 400nm-200nm-400nm and 100nm-50nm-100nm polycarbonate 
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membranes (Avestin, Ottawa, Canada) using a LiposoFast Basic Extruder (Avestin) to 
produce liposomes homogenous in size. This procedure was done while the extruder was 
immersed in 60°C water to keep lipids in a liquid-crystalline phase to facilitate 
extrusion. Keeping the lipids above their transition temperature allows for a greater 
occupied volume due to the highly mobile state of the molecules (Voet and others 2006). 
Filter sterilization of each combination was completed to prevent cross-contamination 
using Acrodisc Tuffryn-HT low protein binding 0.2 µm pore diameter syringe filters 
(Pall Corporation, Ann Arbor, MI).  After extrusion, the unencapsulated material was 
removed by size-exclusion chromatography (SEC). The sample was passed over a Bio-
Gel P-6 DG Desalting Gel column (Bio-Rad Laboratories, Hercules, CA) while using 
0.1X PBS as the system’s buffer.  The sample was then plated on 24-well, flat bottom, 
black upper, lidded microplates (Genetix, Boston, MA) at concentrations of 60mM and 
30mM.  Twenty micro liters of 10% Triton X-100 (Sigma-Aldrich, St. Louis, MO) were 
added to activate the release of calcein.  After the sample was plated, the fluorescence 
strength was measured using an Infinite M200 microplate reader (Tecan, Durham, NC).  
The plate reader was programmed to read excitation and emission wavelengths of 495 
and 515nm, respectively. Fluorescence readings were taken before and after the addition 
of Triton X-100 to estimate the amount of encapsulated calcein within the system.  The 
encapsulation efficiency (EE) percentage was determined using the formula:  
EE (%) = (1 – F/Ft) x 100 
where F is the fluorescence strength before to the addition of Triton X-100, and Ft is the 
fluorescence strength after the addition of Triton X-100 (Were and others 2003). 
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Pathogen Survivor Assay 
 To determine the antilisterial activity of unencapsulated and encapsulated nisin 
within skim and whole milk for extrusion encapsulation method and each liposome 
formulation (PC, PC/PG 7:3, and PC/PG 6:4), pathogen survivor assays were conducted.  
Borden® Ultra-high-temperature (UHT) processed fat free skim milk and whole milk 
(Diversified Foods, Metairie, LA) were used as the experimental food matrix.  In a test 
tube with milk (skim or whole), L. monocytogenes was added to a final inoculum 
concentration of 4 log10 CFU/mL along with liposomes containing encapsulated or free 
nisin at 50 IU/mL that were diluted to a final concentration of 2mM. The ratio of milk:L. 
monocytogenes:liposomes was always kept at 8:1:1 to make sure concentrations of each 
component was consistent between treatments and replications. This was conducted with 
L. monocytogenes Scott A for extruded liposomes and each liposome formulation. There 
was a positive control that only contained L. monocytogenes and no liposomes as well as 
an unencapsulated nisin control which did not contain any liposomes and encapsulated 
nisin within liposomes.  Tubes were then vortexed for ~ 8 seconds and incubated at 5°C 
or at 20°C to model refrigerated storage and temperature abuse, respectively.  Samples 
stored at 20°C were removed from the incubator at time intervals of 0, 1, 3, 6, 12, 24, 
and 48 hr. Samples stored under refrigeration were sampled at the above time points and 
again after 72 hr of incubation. After samples were removed from the incubator, they 
were serially diluted using 0.1% peptone water (Becton Dickinson) and pour plated on 
TSA-YE medium. Once solidified, plates were inverted and incubated aerobically at 
35°C for 48 hours prior to survivor enumeration. 
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Analysis of Data and Experimental Design 
Encapsulation efficiency, as a function of liposome formulation and entrapment 
method, was carried out using a 3x2 factorial: 3 liposome formulations x 2 encapsulation 
methods. Microbiological testing (i.e. pathogen survival) assays were carried out using a 
complete factorial design with balanced means: 3 lipid formulations x 3 treatments 
(encapsulated, free, control) x 2 milk types (skim, whole) x 2 replicates. Sampling times 
were specific to each experimental temperature and were treated as repeated measures; 
experimental temperature was removed from the statistical model as no comparisons 
between samples incubated at 5°C or 20°C were made. For 5°C-incubated samples, 8 
population assays were taken at 0, 1, 3, 6, 12, 24, 48, and 72 hr; samples incubated at 
20°C were assayed at 0, 1, 3, 6, 12, 24, and 48 hr. Overall, the 5°C experimental design 
consisted of 287 degrees of freedom, while the 20°C experiment consisted of 251 
degrees of freedom. Statistical analysis of significant differences between sample means 
was carried out via 2-way analysis of variance (ANOVA) and Tukey's mean separation 
tests with α = 0.05. All statistical analyses were carried out using SPSS 16.0.1 (SPSS 
Inc., Chicago, IL). 
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CHAPTER V 
RESULTS 
 
Liposomal Encapsulation Efficiency of Nisin 
 Liposomes were encapsulated with nisin and calcein to determine the 
encapsulation efficiency percentage (EE) of extrusion based on particular lipid 
formulations. The PC formulation showed a mean EE of 84.20%, while PC/PG 7:3 had 
77.33% and PC/PG 6:4 had 80.78% (Fig. 4). None of the lipid formulations for extrusion 
showed significant differences in the mean EE as determined experimentally. 
 
 
Figure 4-Encapsulation Efficiency of Liposomes Formed via Extrusion.  
Bars represent means of triplicate replications with error bars indicating one standard deviation from the 
mean. Calcein (50 mM) was excited at 490 nm and emission determined at 515 nm. 
 
 
 
 Encapsulation efficiency of nisin was compared against extrusion using freeze-
thaw. The freeze-thaw method produced a non-detectable EE of nisin (Data not shown). 
    53 
   
Survival of L. monocytogenes in Skim and Whole Milk from Liposome-
Encapsulated and Free (Unencapsulated) Nisin at 5°C 
 The survival of Listeria monocytogenes Scott A at 5°C was determined in the 
presence of encapsulated and free nisin in UHT skim and whole fluid milk. Initial 
Listeria counts for all lipid formulations began with 4.5 log10 CFU/mL.  
Listeria grew to a final cell density of 5.0 log10 CFU/mL after 72 hours at 5°C in 
the presence of PC liposomes without nisin (positive control) (Fig. 5). Skim milk with 
PC encapsulated liposomes had a final cell count of 0.90 log10 CFU/mL and free nisin 
reduced Listeria counts to < 1.0 log10 CFU/mL after 72 hour of 5°C incubation (Fig. 5). 
Both encapsulated and free nisin within skim milk caused a reduction in cell density 
significantly different from the positive control across all lipid formulations (i.e. PC, 
PC/PG 7:3, and PC/PG 6:4). PC liposomes with encapsulated and free nisin in whole 
milk at 5°C created a bacteriostatic effect and held Listeria population counts to 4.0 log10 
CFU/mL after 72 hours (Fig. 5).  
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Figure 5-Survivors of L. monocytogenes in Skim and Whole Milk in Presence of 50 IU/mL 
Encapsulated and Free Nisin in 2 mM PC Liposomes at 5°C. 
Symbols represent means of duplicate replications with error bars indicating one standard deviation from 
the mean. 
 
 
 
The positive controls (i.e. skim and whole control) allowed Listeria to grow to a 
final cell density of 5.5 log10 CFU/mL after 72 hours of incubation (Fig. 6). Liposomes 
produced with PC/PG 7:3 lipids at 5°C in skim milk (i.e. encapsulated and free) reduced 
Listeria counts nearly 4 logs with < 1.0 log10 CFU/mL remaining after 72 hours 
incubation (Fig. 6). PC/PG 7:3 liposomes with encapsulated and free nisin in whole milk 
resulted in slight reductions after 24 hours (Fig. 6). However, there was a complete 
recovery of the pathogen after 72 hours incubation with populations equivalent to 4.5 
log10 CFU/mL density that was 0.5 log10 CFU/mL higher than the initial density (Fig. 6).  
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Figure 6-Survivors of L. monocytogenes in Skim and Whole Milk in Presence of 50 IU/mL 
Encapsulated and Free Nisin in 2 mM PC/PG 7:3 Liposomes at 5°C.  
Symbols represent means of duplicate replications with error bars indicating one standard deviation from 
the mean. 
 
 
 
Skim and whole milk positive controls had a final Listeria cell density of 5.0 
log10 CFU/mL after incubation in 5°C for 72 hours (Fig. 7). PC/PG 6:4-entrappped and 
free nisin in whole milk resulted in a decreased cell density following experiment 
completion (3.7 log10 CFU/mL) (Fig. 7). Encapsulated nisin within skim milk resulted in 
reduced counts of ~0.70 log10 CFU/mL and free nisin lower the Listeria population to 
<1.0 log10 CFU/mL within 72 hours (Fig. 7).  
Statistical analysis confirmed lipid combinations (i.e. PC, PC/PG 7:3, and PC/PG 
6:4) were not significantly different from each other at 5°C with respect to the 
populations of L. monocytogenes following experiment completion. 
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Figure 7-Survivors of L. monocytogenes in Skim and Whole Milk in Presence of 50 IU/mL 
Encapsulated and Free Nisin within PC/PG 6:4 Liposomes at 5°C.  
Symbols represent means of duplicate replications with error bars indicating one standard deviation from 
the mean. 
 
 
 
Survival of L. monocytogenes in Skim and Whole Milk from Liposome-
Encapsulated and Free (Unencapsulated) Nisin at 20°C 
The survival of Listeria monocytogenes Scott A in temperature-abused skim and 
whole milk was determined for liposomes with encapsulated and free nisin. Initially, all 
milk samples were inoculated to Listeria cell densities of 4.5 log10 CFU/mL.  
Listeria positive controls grew to a final cell density of 8.0 log10 CFU/mL after 
48 hours of incubation at 20°C for PC liposomes (Fig.8). Both encapsulated and free 
nisin in whole milk had Listeria populations reduced during the first 3 hours, but 
complete recovery of the pathogen occurred following 48 hours of incubation (Fig. 8). 
Liposomes with encapsulated nisin in skim milk had final Listeria cell counts of 7.3 
log10 CFU/mL and free nisin had 5.0 log10 CFU/mL after 20°C incubation for 48 hours.  
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Figure 8-Survivors of L. monocytogenes in Skim and Whole Milk in Presence of 50 IU/mL 
Encapsulated and Free Nisin within PC Liposomes at 20°C.  
Symbols represent means of duplicate replications with error bars indicating one standard deviation from 
the mean. 
 
 
Positive controls for skim and whole milk used during PC/PG 7:3 liposome 
testing showed final cell densities of 8.0 log10 CFU/mL from 48 hours of incubation 
(Fig. 9). Encapsulated and free nisin were able to reduce Listeria populations for 6 
hours; however, populations recovered and maintained exponential growth for 48 hours 
(Fig. 9). Liposomes with encapsulated nisin in skim milk allowed pathogen growth to 
final cell counts of 7.0 log10 CFU/mL whereas, free nisin allowed final cell counts of 2.4 
log10 CFU/mL following 48 hours of incubation (Fig. 9). Encapsulated and free nisin in 
whole milk reduced Listeria growth for the first 3 hours of incubation, but full recovery 
of the pathogen occurred after 48 hours incubation at 20°C. Liposomes with 
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encapsulated nisin had a final Listeria count of ~7.5 log10 CFU/mL while free nisin had 
7.8 log10 CFU/mL (Fig. 9).  
 
 
 
Figure 9-Survivors of L. monocytogenes in Skim and Whole Milk in Presence of 50 IU/mL 
Encapsulated and Free Nisin within PC/PG 7:3 Liposomes at 20°C.  
Symbols represent means of duplicate replications with error bars indicating one standard deviation from 
the mean. 
 
 
 Listeria grew to final cell densities in skim and whole positive controls at 20°C 
during PC/PG 6:4 testing to 8.0 log10 CFU/mL (Fig. 10). Liposome encapsulated nisin 
and free nisin in skim milk were able to reduce pathogen counts during the first 3 hours 
points, but after 48 hours of incubation there was full recovery. Encapsulated nisin had 
Listeria counts of 6.8 log10 CFU/mL and free nisin had 6.4 log10 CFU/mL after 48 hours 
(Fig. 10). Within whole milk encapsulated and free nisin allowed pathogen growth after 
48 hours to 7.7 log10 CFU/mL (Fig. 10).  
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Figure 10-Survivors of L. monocytogenes in Skim and Whole Milk in Presence of 50 IU/mL 
Encapsulated and Free Nisin within PC/PG 6:4 Liposomes at 20°C.  
Symbols represent means of duplicate replications with error bars indicating one standard deviation from 
the mean. 
 
 
 
Statistical analysis showed significant differences between the log means of 
pathogen populations across lipid formulations which was not observed during pathogen 
survivor assays completed at 5°C. Unencapsulated nisin within skim milk was the only 
formulation for which lower cell counts were consistently maintained as compared with 
other treatments. Liposome formulations applied to skim milk consistently lowered 
Listeria cell densities at least 1.0 log10 CFU/mL more than liposomes applied to whole 
milk, with significant statistical differences resulting in L. monocytogenes populations 
between the milks (i.e. skim and whole). However, after 48 hours most cell populations 
had increased to 8.0 log10 CFU/mL. Therefore, exposure of L. monocytogenes to 
liposomal and free nisin did not ultimately inhibit growth of the pathogen.  
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CHAPTER VI 
DISCUSSION  
 It was determined that liposome production by the extrusion method allowed for 
the highest encapsulation efficiency (EE) of nisin. Therefore, it was used for liposome 
production during the antimicrobial assay. All lipid formulations used exhibited EE% 
>50% indicating nisin was successfully entrapped. There were slight differences seen in 
the EE between the three formulations, although analysis of sample means revealed no 
statistically significant differences (p<0.05). PC had the highest entrapment percentage 
while PC/PG 6:4 had a higher entrapment percentage than PC/PG 7:3. These results 
support previously reported experiments where researchers found PC entrapped a larger 
content of nisin than PC/PG formulations (Were and others 2004). However, because 
similar amounts of nisin were entrapped in all lipid combinations it is possible PC/PG 
formulations released the bacteriocin more quickly than PC alone due to differences in 
stability. Adding cholesterol to PC/PG formulations may help increase the membrane 
stability and allow for slower controlled release of nisin. Cholesterol can be used to 
strengthen liposome membranes because it lowers membrane permeability at elevated 
temperatures and modulates membrane-protein interactions (Samad and others 2007). It 
decreases membrane fluidity and creates rigidity from its steroid ring system interfering 
with the motions of fatty acid side chains (Voet and others 2006).  
PC/PG 6:4 was the only lipid formulation that maintained a lower cell density of 
L. monocytogenes than the initial cell count (4.5 log10 CFU/mL) at 5°C (Fig. 4) even 
though statistical analysis confirmed lipid combinations were not significantly different 
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from each other. It was also found that at 20°C the lipid type created statistically 
different mean log counts. It is possible that liposomal charge has an influence on nisin’s 
interaction with bacteria. According to the chemical structure of phospholipids, PC 
liposomes have a net charge of zero while PG-containing liposome have an overall 
negative charge. Listeria also has a negative charge so there may have been electrostatic 
repulsion between the PC/PG liposomes and Listeria’s cell surface that prevented direct 
contact between the liposomes and the pathogen (Were and others 2004). It is possible 
that because direct contact could not occur nisin had to travel within the food matrix 
until it came in contact with the pathogen. The external environment of the food matrix 
may have created interactions that altered nisin’s activity spectrum thus creating 
statistically different means between lipid combinations. 
 Results for 5°C and 20°C indicate an initial reduction or bacteriostatic effect in 
Listeria populations within the first 3 hours, although evidence of pathogen growth was 
observed after 3 hr incubation at 20°C and after 48 hr incubation at 5°C, similar to 
previously reported experiments and expected microbiological growth patterns of L. 
monocytogenes (Figures 4-7) (Song and Richard 1997; Schillinger and others 1998; 
Vignolo and others 2000). Schillinger and others (1998) tested the bactericidal effect of 
nisin (10-500 IU/mL) against L. monocytogenes Scott A and showed that even at the 
highest antimicrobial concentration (500 IU/mL) Listeria numbers did not remain at a 
low level but increased to 104 CFU/mL within 24 hours and to 108 CFU/mL after 48 
hours. Most likely nisin was destroyed during encapsulation or incubation or it simply 
did not destroy all the Listeria cells in the sample. Nonspecific binding of nisin to 
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Listeria cells, nisin bound to dead cells, or sub lethal amounts of nisin bound to Listeria 
are all possible scenarios for pathogen repopulation (Degnan and others 1993). However, 
it is possible that the survivor Listeria cells adapted and became resistant to nisin over a 
period of time. Song and Richard (1997) reported Listeria survivors displayed increased 
resistance towards the bacteriocin they were in contact with. Hurst (1981) reported in 
earlier works that resistant cells were easily obtained by ‘training’ specific bacteria to 
grow in the presence of increasing concentrations of nisin.  
 There are consistent differences in Listeria counts between skim and whole milk 
samples. Therefore, any variable tested with different milk fat percentages will have 
statistically different mean log values. Skim milk (<0.5% milk fat) maintained more 
lower Listeria counts whereas whole milk, with higher milk fat content, did not. The 
presence of milk fat has been shown to reduce the antimicrobial effects of nisin due to its 
interaction and adsorption to fat and the surface of protein globules (Thomas and 
Delves-Broughton 2005; Sobrino-Lopez and Martin-Belloso 2008). Nisin’s amphipathic 
nature allows it to bind to fat in foods which interferes with uniform distribution making 
nisin unavailable for bacterial inhibition (Delves-Broughton and others 1996). Many 
studies have shown the antimicrobial activity of nisin is reduced as the milk fat 
concentration is increased (Jung and others 1992; Bhatti and others 2004; Sobrino-Lopez 
and Martin-Belloso 2008). Bhatti and others (2004) have shown nisin is unavailable to 
react with Listeria’s cell membrane in 2% or higher milk due to present phospholipids 
binding a large portion of the bacteriocin. Skim milk was not affected as significantly 
because less milk fat was present; therefore, similar nisin concentrations were sufficient 
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to disrupt the listerial cell membrane (Bhatti and others 2004). However, at 5˚C whole 
milk was able to maintain a 1.0 log10 CFU/mL lower Listeria population than positive 
controls due to reduced levels of Listeria growth in refrigerated temperatures. Even at 
the highest milk fat content, nisin has an effect on Listeria counts despite its interaction 
with fat globules present. This is important for the industry because a reduction of 1 log 
can mean increased shelf life and safety of the milk and an increase of 1 log has the 
potential to contaminate and create many foodborne illness cases.  
 There are several differences seen in Listeria population counts between the 
encapsulated and free nisin treatments that need to be addressed. The 5˚C and 20˚C 
treatments showed free nisin maintained lower Listeria counts than encapsulated nisin 
within skim milk, and both free and encapsulated Listeria counts were very similar 
within whole milk. In the case of whole milk, nisin probably interacted and became 
bound with the higher amount of milk fat present making it unavailable to act upon and 
reduce the Listeria population. The results show free nisin had better inhibition of the 
pathogen than encapsulated nisin does not agree with previous studies (Benech and 
others 2002a; Benech and others 2002b; Were and others 2004). However, several key 
differences exist between this experiment and previous research findings. There were 
higher amounts of nisin used within previous studies such as 250-300 IU/mL, compared 
to 50 IU/mL used for this experiment (Benech and others 2002b). That study showed a 
correlation of increasing the concentration of nisin with increased entrapment efficiency 
that ultimately led to an increased inhibition of Listeria (Benech and others 2002b). 
Other studies have used broth like Tryptic Soy Broth, beef tallow and beef muscle 
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slurries, or cheddar cheese for the growth medium, while fluid milk was used for this 
study (Degnan and Luchansky 1992; Degnan and others 1993; Benech and others 2002a; 
Benech and others 2002b). These matrices are very different from one another, and it is 
possible these differences attributed to the difference in results. Nisin stability is highly 
influenced by cheese components and storage conditions, which can affect nisin activity 
(Benech and others 2002a; Benech and others 2002b). During cheese ripening, nisin 
peptides may be degraded by proteolytic enzymes or nisinase from lactic acid bacteria. 
Nisin may diffuse to the fat phase of the cheese matrix and contribute to a decline in 
nisin activity (Benech and others 2002b). Cheddar cheese also possesses many factors 
that help suppress the growth of Listeria including lower water activity, slightly acidic 
pH, solid matrix, etc. The fluid milk matrix used for this study was an ideal environment 
for Listeria to flourish. Results confirmed nisin could not compete with Listeria in an 
ideal environment where whole milk was temperature abused for 72 hours.  
 Different methods have been used in previous studies to enumerate bacterial 
growth. Several studies have used spectrophotometers to measure the optical density (i.e. 
turbidity) of experimental samples (Were and others 2004; Taylor and others 2006). 
Spectrophotometers measure the sample cell density as a function of light scattering; 
light scattering techniques are rapid and nondestructive to the cells, but do not measure 
cell numbers or CFU. This can be problematic because it gives a rough estimate of cell 
populations and not an actual count. This study used CFU/mL counts from plated 
Listeria on growth media to enumerate the pathogen. These counts, and counts from 
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studies using optical density measurements, may be different due to their methods of 
measuring cells present.  
 All of these differences between previous studies and the present study are 
possible explanations to the differences seen with free and encapsulated nisin treatments. 
It is possible that little EE% of nisin was achieved within the liposomes and with less 
nisin present Listeria counts were not reduced as well. Another possible scenario is nisin 
was only attached to the surface of the liposomes. The small amount of nisin that was 
surface attached could not have eliminated as much Listeria as free nisin.  
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CHAPTER VII 
CONCLUSION  
 This study compared encapsulation efficiency percentages (EE%) between 
extrusion and freeze-thaw methods. It was determined that extrusion allowed higher 
encapsulation percentages of nisin (i.e. 84.20%, 77.33%, 80.78%) whereas freeze-thaw 
had undetectable fluorophore entrapment. Therefore, extrusion was chosen for liposome 
production during pathogen survivor assay testing.  
 Liposomes were produced using three lipid molar formulations: PC, PC/PG 7:3, 
and PC/PG 6:4 (mol. fraction) with encapsulated and free nisin within skim and whole 
milk. L. monocytogenes was used to determine how well each formulation could 
suppress pathogen growth. It was determined that lipid molar formulations did create 
statistically different log means. Free nisin inhibited Listeria growth more significantly 
at 20°C than encapsulated nisin; however, differences were not as significant in 5°C. 
Milk fat percentages (i.e. skim and whole milk) created statistically significant 
difference at both incubation temperatures. Skim milk was able to reduce and maintain 
lower Listeria counts than whole milk due to smaller amounts of milk fat present that 
kept nisin from interacting with present fat globules. Nisin was able to reduce the 
Listeria population by ~1.0 log10 CFU/mL at refrigerated temperature showing the 
bacteriocin can improve the safety of milk products and overall safety of food 
manufactures within the industry.  
 Further research is needed to improve EE using crude and inexpensive lipids so 
the industry can use these methods on an industrial scale. Liposome design should be 
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studied in the future to improve methods that allow for faster production with less 
variability in encapsulation efficacy. Liposome stability over periods of time (i.e. 
minutes, hours, and days) should be determined by testing fluorescence signal strength at 
normal and abused temperatures and within many different lipids. This will help 
determine how long antimicrobials like nisin are released from liposomes and how long 
they can convey safety measures within a product.  
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